Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10437962 | 1.00 | ESR2 (0.35) | ESR2JAK2JAK3JAK1TYK2 | |
| SCHEMBL7032626 | 0.89 | FAAH (0.31) | JAK2JAK3TYK2FAAH | |
| SCHEMBL5664401 | 0.89 | — | — | |
| SCHEMBL9021546 | 0.81 | CYP2C19 (0.37) | JAK2JAK1TYK2 | |
| SCHEMBL16397376 | 0.81 | — | — | |
| SCHEMBL17729359 | 0.80 | SMYD3 (0.33) | JAK2JAK3TYK2 | |
| SCHEMBL10419433 | 0.79 | CYP2C19 (0.40) | JAK2JAK1TYK2 | |
| SCHEMBL8551055 | 0.79 | CYP2C19 (0.40) | JAK2JAK1TYK2 | |
| Hydrochloric Acid SCHEMBL9022156 | 0.79 | CYP2C19 (0.36) | JAK2JAK1TYK2 | |
| SCHEMBL16982375 | 0.79 | CYP2C19 (0.40) | JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | ESR2 1408/4885JAK2 2277/4885JAK3 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.